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INTRODUCTION  
 Acne Vulgaris is an extremely common disease with increased 
prevalence among adolescents.  Although acne is not a life-threatening 
condition, it can cause substantial morbidity. Acne and resulting scarring 
can have a psychological impact including lowered self image and self-
esteem, social impairment and anger. Even those with minimal acne 
experience psychological effects and for those people, the psychosocial 
burden may be the most significant problem with this disease. It has been 
shown that even clinically mild to moderate acne can be associated with 
higher rates of depression and suicidal thoughts among adolescents than 
other chronic and disfiguring skin diseases. In summary, acne is an 
important condition and appropriate intervention is essential to prevent 
complications such as acne scarring, psychological impacts and 
secondary impaired social function.1  
In the last 25 years, numerous topical and systemic drugs have 
been developed for the treatment of acne vulgaris. 
The primary lesions of acne are the microcomedones, which are 
not visible to the naked eye but require special attention with regard to 
the development of therapeutic strategies. They represent the central 
precursor lesions that evolve into either non inflammatory comedones or 
inflammatory macules, papules and pustules.  
Retinoids are derived from Vitamin A. They were first observed to 
be extremely effective in curing acne since 1962.2  
Retinoids influence the proliferation and differentiation of cells 
and therefore reverse the abnormal desquamation by affecting the 
follicular epithelial turnover. This leads to an expulsion of mature 
comedones and suppression of microcomedone formation. The change of 
the microclimate in the pilosebaceous follicle by prevention of 
hypercornification  promotes an inhospitable aerobic environment for 
P.acnes and is likely to enhance the penetration of other topical drugs. 
Various in Vitro and in Vivo studies also demonstrated direct 
antinflammatory activity of topical retinoids. 2,3 
Furthremore, retinoids modulate the expression of the transcription 
factors, such as AP-1, that regulate genetic expression of growth factors 
and degradative enzymes involved in inflammatory responses Retinoids 
are also involved in the induction of apoptosis by a variety of 
mechanisms either associated with or independent of binding of retinoid 
receptors. 
 
  The results support and give additional theoretical background to 
explain the significant reduction of inflammatory lesions that have been 
observed in well-controlled clinical trials of various formulations of 
adapalene, tretinoin and tazarotene.  
 Retinoids inhibit the formation and reduce the number of 
microcomedones in a dose dependent manner as well as non 
inflammatory and inflammatory lesions. Therefore most acne patients 
benefit from the use of retinoid, whether a topical agent as monotherapy, 
or combination therapy and  subsequent maintenance therapy.  
 Topical retinoids are now used as a first-line treatment for most 
forms of acne, they are also being used as part of maintenance therapy. In 
the face of an increasing prevalence of antibiotic resistant strains of 
P.acnes (i.e. P.acnes do not respond to conventional antibiotics), topical 
retinoids have the potential to minimize antibiotic use in acne. A 
systematic review is hence required to determine both the efficacy and 
the safety of topical retinoids in acne treatment.2,3 
 
 
 
REVIEW OF LITERATURE 
 
 Acne vulgaris is a chronic inflammatory, self-limited disease of 
pilosebaceous unit, seen primarily in adolescents clinically characterized 
by formation of comedones,  papules,  pustules,  nodules,  or pseudo 
cysts and in some cases accompanied by scarring.4 Acne vulgaris is a 
very common physiological malady of adolescents but it is better 
regarded as a disease due to its inflammatory component and the 
disfigurements it produces on the socially and psychologically most 
important body region. 
 The term ‘comedone’ was suggested by Hoeflt (1846).1 Samuel 
plumbe (1795-1837) recognized these primary acne lesions which in 
some patient evolve into papules, pustules and nodules. The importance 
of propionibacterium acnes and sebum in the pathogenesis of acne was 
emphasized by Thibierge (1900). This condition usually starts in 
adolescence5 although (some patients present in the first year of life with 
neo-natal or infantile acne) and frequently resolves by mid twenties. 
Some degree of acne affects 95% and 83% of 16 year boys and girls 
respectively.6 In about 20%, the disease needs the help of physician. A 
peak in the incidence and severity occurs between 14 and 17 years in 
females, 16 and 19 years in male. 
 The highest concentration of acne lesions are found in the 
sebaceous rich anatomic areas of face, shoulders, mid-chest, and upper 
back. The disease is usually self-limited but cases appearing denovo in 
the second and third decade are not uncommon. 
AETIOLOGY AND PATHOGENESIS 
 Although the basic cause of acne is unknown, there is considerable 
information on the various factor concerned in its pathogenesis. Acne is a 
multifactorial disease, developing in the sebaceous follicles.5 
FOUR PRINCIPLE PATHOLOGIC EVENTS IN ACNE ARE: 
1. Seborrhoea 
2. Comedo formation (comedogenesis) 
3. Colonization of the duct with propionibacterium acnes  
4. Mediation of inflammation. 
Seborrhoea 
 Patients with increased sebum production complain of greasy skin, 
Sebaceous activity is predominantly dependent on androgenic sex 
hormones of gonadal or adrenal origin. High level of sebum secretion 
results from high overall androgen production or increased bioavailability 
of free androgen due to deficiency of sex hormone binding globulin 
(SHBG)7. 
 Sebum secretion varies from follicle to follicle and certain follicles 
may be prone to acne. An enhanced peripheral response to androgen must 
be considered as a probable factor in many subjects. 
The possible role of increased 5 α reduction of testosterone to its 
more active metabolite 5α Dehydrotestosterone (5α – DHT) is supported 
by the demonstration of high 5α reductase type I activity in the sebaceous 
gland. This end-organ hyperresponsiveness theory for acne suggest 
that androgen action on sebaceous gland may be independent of serum 
hormonal levels.  
Sebum in acne patients have significant decrease in the level of 
linoleic acid. This results in follicular hyperkeratosis and decrease 
epithelial barrier function.  
 Sebum consists of a mixture of squalene, wax and sterol esters, 
cholesterol, polar lipids and triglycerides. As the sebum moves up the 
duct, bacteria, especially P.acnes, hydrolyse the triglycerides to free fatty 
acids. Lipids may be involved in ductal hypercornification, or may be 
essential to the growth (stimulation and inhibition) of bacteria. Sampling 
of skin-surface lipids has shown that patients with acne tend to have 
higher levels of squalene and wax esters, lower levels of fatty acids, and 
a more frequent occurrence of particular free fatty acids. Linoleic acid is 
significantly reduced in epidermal and comedonal lipids, and this may 
relate to ductal hypercornification. 
Comedogenesis 
 Kinetic studies have demonstrated that there is an increase in 
cellular turnover 11 in comedones and their increased adhesion due to 
persistence of desmosome leads to retention hyperkeratosis. The stimulus 
for hypercornification may be androgen mediated or the result from the 
irritant effect of sebaceous free fattyacids. Androgen mediated 
hypercornification is due to its receptor present in the outer root sheath of 
infra infundibular region of follicles.12 Sebum initiate the infundibular 
keratinocyte leading to release of interleukin 1 alpha. This induces the 
follicular hyperkeratosis. 13, 14 
 Impaired water barrier function is caused by reduced amounts of 
ceramides which are responsible for comedone formation, since barrier 
dysfunction is accompanied by hyperkeratosis of the follicular 
epithelium. Local follicular deficiency of epidermal lipids (free sterol, 
ceramides) and increased sebum glycerides may induce abnormal 
follicular keratinisation. 15 
 Certain external chemicals may contribute to comedogenesis. 
These substances include the ingredients of some cosmetics such as 
isopropyl myristate, propylene glycol, and D and C red dyes. It has been 
suggested that the excretion of products from the sebaceous gland occurs 
through an organized acellular tubular conduit – the sebolemmal sheath 
produced by the sebaceous duct cells; rupture of this sheath may 
contribute to comedogenesis. However, this concept has yet to be 
confirmed by others. 
 
Bacterial Colonisation 
 Bacterial colonization of sebaceous follicles is another important 
contributing factor in the production of acne. Propionibacterium acnes, 
staphylococcus epidermidis and pityrosporum ovale are the primary 
organisms found in the acne patients but propionibacterium acnes is the 
most abundant organism present.16 Ideally for the overproduction of 
propionibacterium acnes, the anaerobic atmosphere of the blocked 
sebaceous follicle with its lipids substrate is useful for the production of 
the free fatty acids, which in turn may be a factor causing retention 
hyperkeratosis. 
 The chemotactic factor released by propionibacterium acnes 
attracts to the follicle. These leucocytes ingests propionibacterium acnes 
with the resultant release of hydrolytic enzyme that damage the follicular 
wall causing it to rupture. The content of the follicle provoke 
inflammatory reaction. The severity of the inflammation in acne 17 is 
determined also by host response to propionibacterium acnes. Antibodies 
IgGI, IgG2, IgG3 to propionibacterium may be involved in the 
pathogenesis of acne.18 
 
Mediation of Inflammation 
 Propionibacterium acnes produce proteases like lipases 
phosphatases, hyaluranate and lyase which mediate inflammation. This 
produce biologically active substances that diffuses into the dermis and 
causes inflammation by activating complement and chemotactic 
neutrophils. 
 There is also increasing evidence to support the involvement of 
toll-like receptors in acne inflammation. Toll receptors recognize 
‘abnormal’ organisms. In a way, Propionibacterium acnes can be looked 
upon as ‘abnormal’ as it is not often present in follicles from subjects 
without acne. The toll receptors in turn regulate the production of 
cytokines which may contribute to acne inflammation. Propionibacterium 
acnes also produces a prostaglandin-like substance which might be 
involved, as non-steroidal anti-inflammatory drugs have an anti-acne 
effect. 
 Cytokines are known to play a role in inflammatory acne. Ductal 
corneocytes constitutively produce inter-leukins (including IL-1-α and 
IL-β and TNF. 
 Leukotriene precursors are synthesized in the sebaceous gland. 
LTB4 induces recruitment and activation of neutrophils and monocytes. 
It also stimulates the production of a number of pro-inflammatory 
cytokines and mediators that augment and prolong tissue 
inflammation.52,53 
 
EVALUATION OF ACNE LESION 
 Microcomedone mature and become epithelial lined follicular cyst 
containing keratinous material, lipid, hair and bacteria.11  Two types of 
mature comedones are produced. The open comedone (black head) 
orifice is widely dilated by a cornified impaction continuous with the 
deeper keratinized lamella. Black colour is due to melanin and oxidized 
lipids in the follicle. The closed comedone (white head) is a small usually 
flesh coloured papules that has a microscopic opening which keeps its 
contents from escaping. 
 
CLINICAL MANIFESTATION 
 The pathognomonic lesion of acne is the comedones, either open 
or closed. As the disease progress papules, nodules, and cyst may appear 
as a single lesion or as a combination of all types. As acne lesion, resolve 
a post inflammatory erythema and even pigmentation can last several 
months before they resolve. 
 The deeper inflammatory process, the more likely it will tend to 
produce permanent scarring which vary from small pits to deep fissures 
and even hypertrophic or keloidal scar. The primary site of scar is the 
face and to a lesser degree the back, chest and shoulder. The courses of 
acne tend to wax and wane. Seasonal variation may be seen. 
 There are also several subtypes of comedones  
 Sandpaper Comedones: consists of multiple very small white 
heads and are found most often on the forehead. 
 Macrocomedones : are large white heads or black heads greater 
than 1mm in diameter. 
 Submarine Comedones : are large comedonal structures greater 
than 0.5cm in diameter. 
 Inflammatory lesions may be superficial or deep. The superficial 
lesions are papules and pustules and the deep lesions are deep pustules 
and nodules. 
 Nodules more frequently occur in males. Nodules and deep 
pustules may lead on to devastating cosmetic effects and scarring. 
Scars may show increased collagen. E.g. hypertrophic scars and keloids 
or be associated with loss of collagen. 
 i.e.  Ice pick scars 
   Depressed fibrotic scars 
   Atrophic macules 
   Perifollicular elastolysis. 
 
GRADING OF ACNE 
The severity of acne can be graded on clinical grounds as 19  
Grade 1 (Mild) : Comedones, Occasional, Papule 
Grade 2 (Moderate): Papules, comedones, few pustules 
Grade 3 (Severe) : Predominant pustules, nodules & abscesses 
Grade 4( Cystic) : Mainly cysts, abscess and widespread scarring 
Various grading and scoring system in acne : 20 
 
MODIFIED COOKS METHOD 
 Reliable method since photographic reference standard is required. 
Used only for facial lesion. Grading ranging from 0-9 is used for one 
group that includes comedones papules and macules.21 
 Overall severity is graded on another scale of 0-8 that also includes 
pustules, nodules and cysts. 
LEEDS TECHNIQUE 
 Complex scores but also includes assessment of lesions over face 
as well as over back and chest. No photographic reference is required. 
Face is divided into right and left halves and counting is done on both 
sides.22 
SEVERITY INDEX MICHAELSON 
 Simple score, by counting number of open or closed comedones, 
papules, pustles and infiltrated lesions. Severity index. 5 for comedones, 
1 for papule, 2 for pustle, 3 for infiltrated lesions, 4 for cystic lesions 23. 
The  total number of lesions including the comedones, papules and 
pustules were counted before the start of treatment and the response 
noted by the reduction of the number of total lesions and graded.  
 
 
PHYSIOLOGICAL & ENVIRONMENTAL FACTORS THAT 
INFLUENCE ACNE  
 
DIET 
 A potential role for diet in acne is controversial. That natural 
hormonal components of milk and / or other bioactive molecules in milk 
could exacerbate acne. 
 High glycemic index, which in turn can trigger insulin and insulin 
like growth factor that influence androgens and retinoids. This could 
thereby induce seborrhoea, comedones and acne. 
 The trend of increased weight among children and earlier puberty 
may be reflected in early clinical acne.24 
Premenstrual Flare 
 Possibly it is related to a premenstrual change in the hydration of 
the pilosebaceous epithelium. Progesterone and oestrogen also have both 
pro and anti inflammatory effects.25 
Sweating 
 Sweating causes a detoriation in their acne. Ductal hydration may 
be the responsible factor.26 
Ultraviolet Radiation 
 UV radiation may enhance the comedogenicity of sebum.27 
Occupation 
 Hydration of the ductal stratun corneum may induce acne in such 
occupations as catering and steam cleaning. Patients dealing with oil may 
develop an acneiform oil folliculitis.26 
Smoking and Acne 
 One study has shown a linear relationship between acne prevalence 
and the number of cigarettes smoked daily.28 
Stress 
 Emotional factors presumably affect acne by altering the adrenal 
pituitary axis.29  
 
UNCOMMON ASSOCIATIONS WITH ACNE 
Acne excoriee 
Apert’s syndrome 
Body dysmorphic disorder and acne 
Darier’s disease 
Folliculitis on the scalp 
 Scalp folliculitis 
 Folliculitis decalvans 
 Dissecting folliculitis of the scalp 
Granulomatous / lymphoedematous acne 
Hidradenitis suppurativa 
Other forms of Acne 
Drug induced acne / acneiform eruptions 
Endocrine acne 
Externally induced acne 
Cosmetic acne 
Pomade acne 
Detergent acne 
Infantile and Juvenile acne 
Mechanical acne 
Occupational acne 
Oil and tar acne 
Chloracne  
Solar comedone 
 Tropical acne 
 
 
 
 
 
DRUGS REPORTED TO CAUSE ACNE / ACNE LIKE 
ERUPTIONS 
 
Hormones and steroids 
 Gonadotrophins, Androgens, Anabolic Steroids and Oral and 
topical steroids 
Halogens 
     Bromides, Iodides and Halothane 
Antiepileptic Drug 
     Phenytoin, Phenobarbitone and Troxidone 
Anti-tuberculous Drugs 
     Isoniazid and Rifampicin 
Miscellaneous 
     Chloral hydrate, Cyanocobalamin, Disulfirum, Lithium, Psoralens, 
Quinine, Thiourea, Thiouracil and Sulphur 
ENDOCRINE ACNE 
The endocrine diseases associated with acne 30 
Cushing’s disease 
Late onset congenital adrenogenital syndrome 
Polycystic ovarian syndrome 
Adrenal / ovarian tumour 
An endocrine evaluation may be indicated for adult females 
With sudden onset of severe acne 
In the presence of hirsutism 
Irregular menstrual periods 
Other signs of hyperandrogenism 
Relapse shortly after starting isotretinoin therapy. 
 
INVESTIGATIONS TO RULE OUT ENDOCRINE ACNE 
 Serum dehydroepiandrosterone sulphate (DHEAS) >21.7µmol/lt – 
adrenal tumour.  
 Congenital adrenal hyperplasia – DHEAS between 10.8-
21.7µmol/lt. 
17α hydroxyprogesterone > 12-8µmol/lt and cortisol level 
increased . 
 Serum Total testosterone increased in the range of 520-700µmol/lt 
and increased LH- FSH ratio > 2-3 in polycystic ovarian disease 
 Serum testosterone very much elevated in case of ovarian tumour 
 An ultrasound abdomen – to rule out PCOD30 
 
 
INFANTILE AND JUVENILE ACNE 
  Infantile and Juvenile Acne, which mainly affects males present as 
facial acne in children between 3 and 24 months, and may last upto 5 
years of age. 
 The individual lesions include comedones, papules, pustules, 
nodules and scarring. Infantile acne is very rarely associated with other 
clinical features of androgen excess such as hirsutism or premature 
closure of epiphyses; very occasionally, there may be transient or more 
persistent high plasma levels of testosterone, LHs and FSHs. An 
associated virilizing tumour or underlying congenital adrenal hyperplasia 
is extremely rare. If the child is otherwise well and there are no other 
abnormal features, no endocrine investigations are required. However, 
such investigations may be appropriate in a patient who develops acne 
between 5 and 8 years of age.   
Severe Acne Variants 
Acne conglobata 
Acne fulminans 
Gram Negative Folliculitis 
Pyoderma faciale 
Vasculitic / Pyoderma gangrenosum acne 
SYNDROMES ASSOCIATED WITH ACNE 
SAHA SYNDROME 
     Seborrhoea, Acne, Hirsutism and Alopecia 
SAPHO  SYNDROME  
Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis 
APERTS SYNDROME 
     Early epiphyseal closure, Hypertelorism, Flattened occiput, Proptosis 
(due to shallow orbits), Prognathism, Parrot beaked nose and Fused 
shortened digits 
TREATMENT FOR ACNE VULGARIS 
     Choice of Topical Treatment 
Predominantly Anticomedonal 
Adapalene, All-trans-retinoic acid, Azaleic acid and Isotretinoin 
Predominantly Antimicrobial 
Azaleic acid, Benzamycin, Benzoyl peroxide, Clindamycin, 
Erythromycin and Tetracycline 
Predominantly Anti-inflammatory 
Adapalene, Nicotinamide, Topical Antibiotics 
ORAL THERAPY 
Oral Antibiotics 
 Tetracycline, Oxytetracycline, Doxycycline, Minocycline and 
Azithromycin 
 
 
Hormonal Treatments 
 Predisolone plus oestrogen, Oestrogens plus antiandrogens, 
Spironolactone 
Oral Retinoid 
     Isotretinoin 
Other Oral Treatment 
Oral zinc, Non steroidal anti inflammatory drugs and Oral Vitamin A 
Treatment of Scars 
 Scar excision, Dermabrasion and laser resurfacing, Collagen 
Injection, Gelatin Matrix implant, Chemical Peeling and Cosmetic 
Camouflage 
TOPICAL TREATMENT OF ACNE 
     Patients with mild acne will do well with only topical treatment; those 
with more severe and recalcitrant acne will require systemic medication. 
The ideal acne treatment would be entirely topical to avoid systemic 
effects. It would reduce abnormal keratinization, inhibit sebum 
production, and limit the production and activity of Propionibacterium 
acnes. 31 
Tretinoin 
        Since the pioneer study by Kligman et al. in 1969, topical tretinoin 
has become a standard agent in the treatment of acne.  Although the exact 
mode of action of tretinoin is unknown, current evidence suggests that 
topical tretinoin decreases cohesiveness of follicular epithelial cells with 
decreased microcomedone formation. Additinally, tretinoin stimulates 
mitotic activity and increased turnover of follicular epithelial cells 
causing extrusion of the comedones. This in turn reduces the number of 
inflammatory lesions resulting from the eventual rupture of the micro 
comedones. 31, 32 
 
Side Effects 
     Mild erythema, Peeling, Severe dryness, Local irritation and 
photodermatitis 
 
Topical Isotretinoin 
     Topical isotretinoin was developed as a safer alternative to the oral 
medication. Although effective in mild to moderate inflammatory and 
non inflammatory lesions, it works only by affecting abnormal follicular 
keratinization. It has no effect on sebum production. 32, 33 
 Adapalene 
     Adapalene is a synthetic derivative of naphthoic acid with retinoid-
like activity. Adapalene is a modulator of cellular differentiation, 
keratinization, and inflammatory processes suggesting that its therapeutic 
role is both as a comedolytic agent as well as an anti-inflammatory agent. 
Tazarotene 
     It has bene shown to be effective in an active treatment for 
inflammatory and non-inflammatory lesions, especially with stubborn 
comedones. 
Salicylic Acid 
     Salicylic acid is effective against comedones and inflammatory 
lesions in acne vulgaris. It represents a useful but less effective option for 
patients unable to moderate treatment  with tretinoin, because its 
comedolytic activity is only approximately 25% that of tretinoin.34 
TOPICAL ANTIMICROBIALS 
Benzoyl Peroxide 
      Benzoyl peroxide is a powerful oxidizing agent and antimicrobial that 
works by decreasing the population of Propionibacterium acnes. It is 
most effective for inflammatory acne consisting of papules and pustules. 
Clinical studies show a modest reduction in comedones, probably as an 
indirect effect. 35 
Side Effects 
 Irritation, Redness and  Scaling 
Topical Antibiotics 
     Topical antibiotics are most useful in the management of mild 
inflammatory acne. They can be the initial treatment modality or used as 
a adjunct to treatment with tretinoin or benzoyl peroxide. Bacteriostatic 
antibiotics are thought to improve acne by decreasing the formation of 
by-products, but not necessarily the actual number of Propionibacterium 
acnes. Sublethal levels of antibiotic are able to reduce the promotion of 
chemotactic factors by Propionibacterium acnes that play an important 
role in the disruption of chemotactic factors and the promotion of 
subsequent inflammation. Papular and pustular acne respond best with 
topical antibiotics.37 
Topical Azelaic Acid 
     Patient with predominantly inflamed lesions should received topical 
azelaic acid, benzoyl peroxide or topical antibiotics.36, 37  
 
 MISCELLANEOUS TOPICALS 
Nicotinamide,  Drying and Peeling Agents 
 
COMBINATION THERAPY 
 Because of acne’s multifactorial orgins, most patients respond 
better if therapy encompasses more than one area of pathophysiology. 
Combination therapy is therefore rational and effective,  
 The efficacy of benzoyl peroxide and topical antibiotics may be 
increased by concurrent therapy with tretinoin, because tretionin 
increases the cutaneous penetration of other topically applied agents. 
Benzoyl peroxide and topical antibiotics may exert a synergistic 
antimicrobial effect when used together; a preparation consisting of 3% 
erythromycin and 5% benzoyl peroxide in a gel base is more effective in 
the improvement of inflammatory acne than either agent alone. 
 Treatment of inflammatory acne with a sequential regimen of 
topical tretinoin and BP/erythromycin gives good response. 36, 37 
 
 
 
 
TOPICAL  RETINOIDS 
 
INTRODUCTION  
 In topical preparation, retinoid are widely used as prescription 
drugs as well as cosmeceuticals. 
 In 1976, Michael Sporn and his colleagues originally defined 
retinoids as both the naturally occurring compounds with Vitamin A 
activity and the synthetic analogues of retinoid.38 
 Now retinoid is defined as any molecule that, by itself at or 
through metabolic conversion, binds to and activate the retinoic acid 
receptors.   
 Topical retinoid have been used in acne therapy since 1962 and the 
first substance to be studied was tretinoin. Their biological effects are 
mediated and regulated by nuclear hormone receptors (Retinoid acid 
receptors (RAR), retinoid X receptor (RXR) and cytosolic binding 
proteins. Each receptor family includes, three subtypes (α, β,γ ) that 
induce expression or down regulation of target genes in a ligand 
dependent manner.39 
 
HISTORY 
 The history of the development of retinoids in dermatology 
comprised of three generations. The first is nonaromatic retinoids, 
which include tretinoin – (retinoic acid) and isotretinoin (13 cis retinoic 
acid). Both can be used as topical or systemic treatment.39 
 The second generation retinoids are monoaromatic retinoids 
etretinate and its metabolite acitrolin, which are only effective as a 
systemic treatment. The third generation retinoids are polyaromatics i.e. 
adapalene, tazarotene δ Baxorotene.  
 The most studied retinoids for topical acne treatment worldwide 
are tretinoin and adapalene. Depending on country and indication 
tazarotene, isotretinoin, motretinide, retinoide β glucunonide and 
retinaldehyde are also available for acne treatment.40 
 
RETINOID RECEPTORS 
     The discovery and characterization of retinoic and receptors (RARs) 
as having molecular features that are similar to steroid / thyroid hormone 
receptors were land mark findings.  
 They bind to regulatory regions in DNA called hormone response 
elements or target sequences and activate gene transcription in a ligand 
dependent manner. 
 Human epidermis expresses RAR α, RAR γ, RXRα. RXR β, 
messenger RNAS. 
 There relative levels of retinoid receptor and MRNAS mirror their 
relative protein levels. 
 For RAR proteins 87% are RAR  γ, and 13% are RAR α with no 
detectable RARβ of the RXR proteins, 90% are RXR  α. 41    
 
RECEPTOR SELECTIVE RETINOIDS 
 Synthetic molecules could be screened for their ability to bind to 
and activate specific receptors. 
 Many of these compounds still considered as retinoids by virtue of 
their ability to activate the receptors. 
 Adapalene has restricted receptor specificity possessing poor 
affinity for  RAR-α , higher affinity for RAR-β & γ, and no interaction 
with RXR-α. Tazarotene cannot directly binds to RARS or RXRs. Its 
metabolite, tazarotenic acid has receptor selectivity for RARS. 42 
     
MECHANISM OF ACTION  
      
 Retinoid action are mediated by retinoid receptors. RARs are 
transcription factors, so the skin effects of retinoids must be through 
regulated gene expression. 
 The best mechanism is activation of retinoid target genes through 
direct binding to retinoic acid responsive elements (RARE) in the gene 
promotion thereby stimulating the basal transcriptional machinery. 
 RARE regulated genes will be identified that encode for proteins 
that function to modulate cutaneous growth and differentiation. These 
protein products activate other non-RARE containing genes to produce 
the clinical features of retinoid action in skin.41, 42 
 
CELLULAR METABOLISM OF NATURAL RETINOIDS AND 
MOLECULAR MECHANISM OF RETINOID SPECIFIC GENE 
ACTIVATION 
 
      Retinoid delivered to a cell is bound to cellular retinoid binding 
protein 1 (CRBP).  Retinoid can be esterified, via lecithins: retinol acyl 
transferace (LRAT) and stored as retinoid esters.  
Hydrolysis of retinol ester by its hydrolase yields free retinol. 
 Sequential oxidation of retinol generates retinoid acid which is 
bound to cellular retinoic acid binding protein (CRABP). All trans 
retinoic acid can be isomorized to 9 cis retinoic acid. Hydroxylation of 
transretinoic acid by cytochrome P 450 enzyme CYP 26 generates 4 
hydroxy retinoic acid which is inactive.  
 In human skin, RAR α and RXR α heterodimers bound to RARE – 
response elements and transduce retinoid effects in the presence of RAR 
ligands. 41, 42 
 
MOLECULAR MECHANISM OF RETINOID INDUCED 
EPIDERMAL HYPERPLASIA 
 
  Topical retinoid activates RAR/RXY heterodimers in suprabasal 
keratinocytes, causing activation of transcription factors. 
 Heparin binding epidermal growth factor and amphiregulin are 
activated, and this leads to proliferation of basal keratinocytes thickened 
epidermis and peeling / flaking of the stratum corneum. 
 
MECHANISM OF TOPICAL RETINOID IN ACNE 
VULGARIS 
      Retinoids influence the proliferation and differentiation of cells and 
therefore reverse the abnormal desquamation by affecting the follicular 
epithelial turnover. This leads to expulsion of mature comedones (open 
and closed type) and suppression of microcomedone formation. 42, 44 
 The change of microclimate in the pilosebaceous follicle by 
prevention of hyperconification promotes an inhospitable aerobic 
environment for P acnes and is likely to enhance the penetration of other 
topical drugs. 
 An indirect immunomodulatory effect takes place by changing the 
follicular environment and also has anti-inflammatory effect. 
 Another benefit of topical retinoids is their ability to reduce post 
inflammatory hyperpigmentation.  
 Retinoids are especially suitable for maintenance treatment 
because of their multifactorial antiacne efficacy without undesirable 
effects during long term treatment and their ability to prevent micro 
comedone formation. 
 Concerning safety precautions, one has to be aware that topical 
retinoid therapy has not been established in patients younger that 12 
years and women of child bearing age need to be warned of the potential 
risk of teratogonicity and recommended adequate birth control 
measures.45 
 The effect of a retinoid topically applied on the skin is dependent 
on the stability of the substance, its ability for tissue penetration,  the 
cellular uptake and  the intracellular metabolism. 
 Topical retinoid alone or in combinations are regarded today as 
first line treatment for both comedogenic and inflammatory acne. 
 
CLINICAL USE OF TOPICAL RETINOIDS 45 
Approved Indications   : Acnevulgaris 
      Psoriasis 
      Photoaged Skin 
Unapproved Indication  : Post inflammatory hyperpigmentation 
      Melasma 
      Early stretch marks 
      Cosmetic Indication  
      Actinic Keratoses 
Adverse effect of topical retinoids  
Skin irritation, Xerosis, scaling, Itching,  Erythema, Peeling 
 
Uses of Topical Retinoids 
Tretinoin    ; Mild / Moderate acne 
    Photoaging 
    Biological skin aging 
Isotretinoin   : Mild / Moderate acne 
Aliretinoin   : AIDS related Kaposi’s sarcoma 
Motretinide  : Mild / Moderate Acne 
Adapalene   : Mild / Moderate Acne 
Tazarotene   : Mild / Moderate Acne 
Retinol   : Cosmetic Indications  
Retinol Palmitate : Cosmetic Indications 
Retinaldehyde : Cosmetic Indication 
ADAPALENE 
Adapalene a naphthoic acid is a third generation retinoid 
Adapalene was approved in 1996 by the U.S. Food and Drug 
Administration for use in the treatment of acnevulgaris.48 
MECHANISM OF ACTION  
 The drug respectively interacts with only the 6 and 9 sub types of 
the nuclear retinoic acid receptors (RARS). This is in contrast to the 1st 
generation retinoid, tretinoin which binds for all RARS and also to 
cytosolic retinoic acid binding protein (CRABP) 
  Selective binding of adalapalene to retinoic acid receptors is 
believed to contribute to its lesser capacity to cause irritation and greater 
patient acceptability.48 
 Adapalene has been demonstrated to penetrate the sebaceous 
follicles within five minutes of its application on the skin. 
 Adapalene has rapid onset of action and a particularly favourable 
tolerability profile compared with other retinoids. 
 Adapalene is therefore assured of a role in the first line treatment 
of acne vulgaris. 
 Some additional properties such as increased chemical and light 
stability rigidity, and high lipophilicity are purported to cause reduced 
risk of photo-instability and local skin irritation, possibly enhancing 
compliance. 
 
EFFECTS ON CELLULAR DIFERENTIATION AND 
PROLIFERATION 
 
 Although the exact mode of action of adapalene is unknown, it is 
suggested that topical adapalene may normalize the differentiation of 
follicular epithelial cells resulting in decreased microcomedone 
formation. It is thus, a modular of cellular differentiation, keratinization, 
and inflammatory processes, all of which represent important features in 
the pathology of acne vulgaris. Adapalene has restricted receptor 
specificity possessing, higher affinity for RARβ and RAR λ and poor 
affinity for RAR α. 49 
COMEDOLYTIC EFFECT 
 It causes a dose related reduction in the number of  comedones and 
an increase in comedone profile and epidermal thickness.  
ANFI-INFLAMMATORY EFFECTS 
 Adapalene causes 5 – and 15-lipoxygenase activity inhibition and 
cyclooxygenase inhibition (100 times less than lipoxygenase inhibition). 
These effects have been demonstrated in vitro and in-vivo. 
PHARMACOKINETICS 
 Absorption through human skin is low. Only trace amounts 
(<0.25ng/ml) of parent substance have been found in the plasma of acne 
patients following chronic topical application of adapalene in controlled 
clinical trials. Adapalene is very stable on the skin. In the gel 
formulation, restriction on particle size to 3-10m has been shown to 
optimize delivery to the pilo-sebaceous unit. Very little drug penetrates 
the skin, and that which does remains mainly in the epidermis, with some 
progressing to the dermis. Absorbed drug has a half life of about 13 
hours.49 
 
DOSAGE AND ADMINISTRATION 
 Adapalene applied once a day to affected areas after washing the 
face before retiring to bed. A thin film of the adapalene should be 
applied, avoiding eyes, lips, and mucous membranes. During the early 
weeks of therapy, an apparent exacerbation of acne may occur due to the 
action of the medication on previously unseen lesions and should not be 
considered a reason to discontinue therapy. Therapeutic results would be 
noticed after eight to twelve weeks of treatment.48 
ADVERSE REACTIONS 
 Erythema, scaling, dryness, pruritus, and burning will occur in 10-
40% of patients. Pruritus or burning immediately after application also 
occurs in approximately 20% of patients. Approximately 1% or less of 
patients seen with skin irritation, burning / stinging, erythema, sunburn, 
and acne flares. These are most commonly seen during the first month of 
therapy and decrease in frequency and severity thereafter. All adverse 
effects are reversible upon discontinuation of therapy.49 
 
DRUG INTERACTIONS 
 Concomitant use of other potentially irritating topical products 
(medicated or abrasive soaps and cleaners, soaps and cosmetics that have 
a strong drying effect, and products with high concentrations of alcohol, 
astringents, spices or lime) should be approached with caution as 
ADAPALENE has the potential to produce local irritation in some 
patients. 
 Caution should be exercised in using preparations containing 
sulfur, resorcinol, or salicylic acid in combination with ADAPALENE, if 
these preparations have been used it is advisable not to start therapy with 
ADAPALENE until the effects of such preparations in the skin have 
subsided. 
OVERDOSAGE 
 ADAPALENE is intended for cutaneous use only. If the 
medication is applied excessively, marked redness, peeling, or discomfort 
may occur. 
CONTRAINDICATIONS 
 Hypersensitivity to adapalene or any of the components in the 
vehicle gel. 
 
PRECAUTIONS 
General 
  Exposure to sunlight should be minimized. 
  Use of sunscreen products and protective clothing is 
recommended when exposure cannot be avoided. 
  Avoid contact with eyes, lips, angles of the nose, and mucous 
membranes. The product should not be applied to cuts, abrasions, 
eczematous skin, or sunburned skin. 
  Certain cutaneous signs and symptoms such as erythema, dryness, 
scaling, burning, or pruritus may be experienced. These are most likely to 
occur during the first two to four weeks and will usually lessen with 
continued use of the medication. 
 
PREGNANCY 
     Adapalene should not be used during pregnancy. 
 
NURSING MOTHERS 
     Caution should be exercised when Adapalene is administered to a 
nursing woman.48 
 
PAEDIATRIC USE 
     Safety and effectiveness in paediatric patients below the age of 12 
have not been established.48 
 
TAZAROTENE 
 It is a receptor selective retinoid. Tazarotene is a synthetic 
acetylonic retinoid that penetrates the skin and is converted to an active 
metabolite, tazarotenic acid.  
Mechanism of Action 
 It is a receptor selective retinoid, efficacious in the treatment of 
patients with acne vulgaris. 
 Tazarotene itself does not bind to retinoic acid receptors (RADs), 
however tazarotenic acid binds with high affinity to the RARs with the 
rank under of affinity being RARβ>RARα > RARγ. It is effective in 
reducing inflammatory lesions as well as non-inflammatory lesions. It 
normalizes keratinocyte differentiation, reverses keratinocyte 
hyperproliferation. Reduction in comedone counts was greatest when 
tazarotene 0.1% was used as first line therapy.49 
Mode of Application  
 In the treatment of facial acne, patients are instructed to apply a 
thin film to cover the entire face. It is important to treat the entire face in 
order to treat and prevent microcomedone formation. 
 Tazarotene is initially applied for 2 minutes, then washed off with 
soap and water. The time can be increased by 1 minute every 3 days to a 
maximum of 5 minutes as tolerated. The contact time is reduced to 3 
minutes if irritation occurs, then gradually increased to 5 minutes as 
tolerated. 
SIDE EFFECTS 
Skin irritation, Peeling, Erythema, Dryness, Burning and Itching 
  They are most common during the first 1-2 weeks of therapy and 
can be minimized with use of cream formulation, alternate day 
application. 
Contra Indications 
  Children under 12 years of age, Nursing Women,  Pregnancy, 
Hypersensitivity to tazarotene or any of the components in the vehicle. 
 Of the different clauses antiacne medications, retinoids are thought 
to be the best, because the only agent to normalize the abnormal 
follicular epithelial differentiation / desquamation viewed to be in the 
pathogensis of acne lesions. 49, 50, 51 
 
 
 
 
  
 
AIM OF THE STUDY 
 
 The aim of the study is to compare the efficacy of topical 
adapalene and topical tazarotene in the treatment of acne vulgaris with 
each other. 
 
 The agents compared were the following:- 
1) 0.1% Adapalene cream 
2) 0.1% Tazarotene Cream 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 One hundred patients of either sex were enrolled and randomly 
assigned for the above study. The study was singleblind randomized open 
prospective comparative clinical trial. It was carried in the Department of 
Dermatology, Government General Hospital, Chennai during the period 
of  August 2006 to August 2008. 
 
Inclusion Criteria 
Patients of either sex with mild to moderate acne vulgaris 
Exclusion Criteria 
Pregnant and Lactating Women 
Drug induced Acneform eruptions. 
Drug allergy 
Children less than 12 years 
Treatment Protocol and Methodology 
• Patients selected were informed about the nature of study and 
consent was obtained from them. 
• The demographic datas such as age and sex of the selected 
patients, occupation, marital status and duration of the disease 
were taken. 
• Other histories like family history of acne, past and present history 
of topical and systemic treatments were noted and patients were 
advised to avoid other treatments for acne. 
• The precipitating factors for acne such as premenstrual flare, 
summer exacerbation and stress were noted.  History of smoking 
also  was noted. 
• The other features of hyperandrogenism such as irregular 
menstruation, oligomeorrhoea and hirsutism were noted . 
• Patients were subjected for general and systemic examination. A 
thorough dermatological examination was done and other existing 
dermatological lesions apart from acne were recorded. 
• Number of comedones, papules and pustules counted and graded. 
• The 100 patients who fulfilled the inclusion criteria were selected 
randomly and assigned into two groups. 
 Ist  Group - Adapalene 0.1% Cream 
 IInd Group - Tazarotene 0.1% Cream 
• Clinical photographs of the lesions were taken before 
commencement of therapy and after completion of therapy. 
• Patients were instructed to review for every two weeks and report 
the severe side effects, if any, immediately.  
• Married female patients were advised oral contraceptive therapy 
during this treatment. 
• The aforesaid study was conducted for 12 weeks. 
 
Method of Application 
 The patients were advised to avoid cosmetics and other topical 
application over the face. 
Group - I 
 0.1% adapalene cream 
 Adapalene applied once a day over the entire face before retiring to 
bed. After washing the face, patient was advised to apply a thin film of 
the adapalene cream, avoiding contact with eyes, lips and mucous 
membrane. Adapalene was initially applied for an hour then washed off  
with soap and water. The time can be increased gradually, can be applied 
overnight if there is no irritation or any other adverse effect. 
 
 Group – II 
 0.1% Tazarotene Cream  
 Tazarotene applied once a day over the entire face  before retiring 
to bed. After washing the face,  patients were advised to apply the 
tazarotene cream initially for 2 minutes then washed off  with soap and 
water. The time can be increased gradually upto 5 minutes. If the 
irritation is very severe the duration should be reduced to 3 minutes. 
During application, contact with eyes, lips and mucous membrane should 
be avoided. 
 For both the groups patients were instructed about the side effects 
of topical retinoids  such as dryness, erythema, skin irritation, skin 
peeling and itching. Patients were reviewed every two weeks and report 
the severe side effects, if any, immediately. 
  During each visit, the response to the therapy and side effects were 
noted. Patients were also instructed to avoid sun exposure by using sun 
protective measures . 
 
 
 
OBSERVATIONS 
 
 The following observations were made in the present study. 
Among the 100 patients under study, 65 were males, 35 were females. 
They were in the age group ranging  from 15 years to 29 years. 73 
patients were students, others were employees and housewives. 
 The duration of acne ranged from 6 months to  8 years with a mean 
of 17 months.  
 31% of patients had family history of acne. The following 
precipitating factors were recorded as per history from the patient. 
 Premenstrual flareup was noted in 15% patients. 
 Summer Exacerbation in 23% of patients.  
 35% patients were associated with stress, such as education and 
unemployment. 
 30% of patients had associated history of smoking. 
 
 History of previous topical application was present in 30% of 
patients. The time interval between the last and present topical therapy 
was between 6 months to 3 years. 10% of patients had treatment with 
systemic antibiotics. None of them had systemic retinoid treatment. 
Details of topical application were not available with some patients . 
 
 Of the 100 patients 38 patients had Grade I acne and 62 patients 
had Grade II acne.The dermatological conditions  associated with acne in 
this study were  
 Tinea Versicolor, Vitiligo, Polymorphic light eruption and  
 Seborrhoeic dermatitis 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SEX  DISTRIBUTION 
 
Male Female 
65% 35% 
 
 
 In this study, Acne vulgaris showed increased prevalence 
among males.  
 
 
 
 
 
 
 
 
 
  
 
SEX DISTRIBUTION 
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AGE DISTRIBUTION 
 
Age Male  
(N-65) 
% Female  
(N-35) 
% 
15-20 39 60% 20 57% 
21-25 20 30.7% 13 37% 
26-29 6 9.2% 2 5.7% 
 
 Regarding age distribution , the increased prevalence was 
noted in the age group of 15 to 20 years irrespective of sex.  
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THE FOLLOWING OBSERVATIONS WERE MADE IN THIS 
STUDY 
 
 Male (65) Female (35) 
Students 45 28 
Other Occupation 12 5 
Unemployed 8 - 
Housewives - 2 
 
 In the above study, pronounced incidence of acne vulgaris 
was noted among  students.  
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PRECIPITATING FACTORS ASSOCIATED WITH ACNE 
VULGARIS  
(IN PERCENTAGE) 
 
 
 Male  Female  
Summer Exacerbation  15 8 
Stress 20 15 
Premenstrual Flare - 15 
Smoking 30  
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ASSOCIATED OTHER SKIN DISORDERS WITH ACNE 
VULGARIS 
 
       Diseases                Male  
( n ) 
           Female 
 ( n ) 
Pityriasis versicolor 4 2 
vitiligo 2 - 
Polymorphic light 
eruption  
5 4 
Seborrhoeic dermatitis 7 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The therapeutic response observed in patients treated with topical 
adapalene (0.1% cream) 
 
 There was moderate to good response following treatment 
with adapalene(0.1% cream). After about 6 weeks the total number of 
lesions came down to 42%. At the end of 8 weeks 60% of the lesions 
subsided. At the end of 12 weeks, the overall reduction rate was 80.3%. 
 
TABLE – I 
Observation of responses with topical adapalene in Group I patients 
with acne (N-50) 
 
 
Average number of lesions (weeks)  
0 2 4 6 8 10 12 
Average 
number of 
lesions 
reduced  
Percentage 
Reduction 
Comedones 8.2 7.0 6.1 5.0 3.8 2.8 2.2 6.0 73.1% 
Papules 5.3 5.0 4.8 3.6 2.2 1.4 0.8 4.5 84.9% 
Pustules 1.8 1.0 0.6 0.2 0.0 0.0 0.0 1.8 100% 
Total 
Lesions 
15.3 13.0 11.5 8.8 6.0 4.2 3.0 12.3 80.3% 
 
 
 
 
 
 
 
 
The therapeutic response observed in patients who have been treated 
with topical tazarotene(0.1% cream) 
 
Average number of lesions (weeks) 
 0 2 4 6 8 10 12 
Average 
number of 
lesions  
reduced 
% 
Reduction
Comedones  8.4 8.0 7.6 6.4 5.8 5.0 4.1 4.3 51.1 
Papules 4.6 4.0 4.0 3.6 3.4 3.3 2.1 2.5 50.40 
Pustules 0.5 0.5 0.5 0 0 0 0 0.5 100.00 
Total 
Lesions 
13.5 12.5 12.1 10.0 9.2 8.3 6.2 7.3 54.07 
 
 
 This study shows, there was a mild improvement with topical 
tazarotene cream application. After about 4 weeks, the percentage 
reduction was 7.70% only. At the end of 8 weeks the reduction rate was 
29.8%. At the end of 12 weeks the over all reduction rate was 54.07%. 
 
 
 
 
 
The therapeutic response according to Age Group 
 
Group - I 
TOPICAL ADAPALENE 0.1% Cream  
Response Age Group 
Mild Moderate Good 
15-20  13 15 
21-25  4 9 
26-29  2 7 
 
 
Group - II 
TOPICAL  TAZAROTENE 0.1%  Cream 
Response Age Group 
Mild  Moderate Good 
15-20 2 11 2 
21-25 8 4 1 
26-29 7 2 - 
 
 In this study, both Group – I & II patients showed moderate 
to good response in the age group of 15-20 years. 
 
 
COMPLICATIONS 
 During the treatment with topical 0.1% adaplene cream , the 
side effects observed were minimal and it was transient for a short 
period. More common side effects observed with this treatment were 
erythema, dryness, skin irritation and itching. 
 
 Treatment with topical tazarotene showed severe and long 
lasting erythema   and skin peeling leading to poor patient compliance . 
Because of the severe side effects with topical tazarotene, the duration of 
daily topical application was restricted to 3 minutes only.  
Side effects observed during therapy 
Side Effects Group – I 
Adapalene 0.1% 
Group – II 
Tazarotene 0.1% 
Erythema 10 14 
Skin burning   10 15 
Peeling  5 
Dryness 2 20 
Exacerbation  6 - 
Itching 7 8 
Infections - - 
 
 
 
 
SIDE  EFFECTS 
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The response following the therapy for both Group I & II 
 
Nil :  0 to 25% reduction of acne lesions 
Mild :  26 to 50% reduction of acne lesions 
Moderate :  51 to 75% reduction of acne lesions 
Good :  76 to 100% reduction of acne lesions 
 
Response Adapalene 
 0.1% Cream 
 
Tazarotene  
0.1% Cream 
Nil - 3 
Mild - 27 
Moderate 19 17 
Good 31 3 
 
 According to this study , of the patients treated with 0.1% adaplene 
cream , 19% of the patients showed moderate response and 31% showed 
good response. 
 According to this study , of the patients treated with 0.1% topical 
tazarotene cream, 27% of the patients showed mild response, 17% with 
moderate response and  3% showed good response. 
 
 
 
 
Comparison of patients treated with topical adapalene and topical 
tazarotene  (average number of lesions) 
 
 
 
Weeks Adapalene Tazarotene <13.5 
2 13.0 12.5 
4 11.5 12.1 
6 8.8 10.0 
8 6.0 9.2 
10 4.2 8.3 
12 3.0 6.2 
% of Improvement 80.3% 54.07% 
 
 In this study, the overall improvement after 12 weeks of treatment 
with topical adapalene was 80.30% and with topical tazarotene it was 
54.07%. 
 
 
 
 Comparison of Percentage of reduction of acne lesions after every 2 
weeks 
 
Weeks Group – I Group – II 
2 15 7.4 
4 25 7.7 
6 42 25.9 
8 60 29.8 
10 73 31.8 
12 80.3 54.07 
 
 
 
 
 
 
 
 
 
 
  
COMPARISON OF PERCENTAGE  REDUCTION OF 
ACNE LESIONS AFTER EVERY 2 WEEKS 
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COMPARISON OF REDUCTION OF ACNE LESIONS 
AFTER EVERY 2 WEEKS IN PERCENTAGE 
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0.1% Adapalene Cream 
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Treatment  
with  
0.1% Tazarotene Cream 
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DISCUSSION 
 
 Acne vulgaris, the “Stigma of Adolescence” exceeds all other 
causes of suffering in adolescence age group. Many patients do not seek 
physician’s advice. Many cosmetically conscious adolescents who are to 
be married shortly came for treatment, however mild the condition may 
be. In this study, the increased prevalence of acne among students 
signifies its direct correlation with increased sebaceous activity. 
 
 Family history of acne vulgaris was present in 31% of patients. 
Hereditary factor in the causation of acne has been documented. 
  
 15% female patients reported pre-menstrual flare up, this is said to 
be due to pre-menstrual change in the hydration of pilosebaceous 
epithelium. Exacerbation of acne lesion during the time of physical and 
mental stress and summer exacerbation have all been observed. 
 
 Acne therapy aims at reduction of sebum production, correcting 
the abnormal ductal keratinisation, reducing the colony of 
propionibacterium acnes and preventing the release of inflammatory 
mediators that are basically responsible for the pathogenesis of acne. 
 
GROUP – I 
 Patients in this group showed a moderate to good response and 
there was greater  reduction of inflammatory and non inflammatory acne 
lesions. At the end of 4 weeks, there was 25%  reduction of acne lesions 
and at the end of 8 weeks, the reduction rate was 60%. At the end of 12 
weeks of treatment, there was moderate to good response, and the 
reduction at that time was 80.3%. 
 
 The side effects such as irritation, itching, dryness, erythema, skin 
peeling were seen among few patients. There side effects were very 
minimal and transient compared to topical 0.1 % tazarotene cream. 
During treatement with topical 0.1% adaplene cream patient compliance 
and overall outcomes were good. Patients showed up for regular and 
proper treatment. The side effects were observed among few patients 
only, most of the patients had no side effects . 
 
GROUP – II 
 Patients in this group showed a mild response in both 
inflammatory and non inflammatory lesions. The side effects were very 
severe in this study. Most of the patients developed  erythema, scaling, 
dryness during the Ist week of therapy. The side effects observed in this 
group were prolonged and severe compared to topical adapalene.  
At the end of 4 weeks of treatment, the reduction rate was 7%.   
At the end of 12 weeks, the overall reduction was 50.04% 
 
 The side effects which have been seen in this study has also been 
noted in the literature.54, 55 
 
 Overall, there is moderate to good improvement in the acne lesions 
with topical 0.1% adapalene cream. Topical treatment with 0.1% 
tazarotene  showed mild improvement with more side effects. 
 
 The overall improvement with topical 0.1% tazarotene which were 
found in the literature were not noted in this study. 54, 55, 57 
 
 According to previous studies conducted at various institutes and 
research centres 56,57 , the side effects observed with topical adaplene 
cream were significantly lower than that of topical tazarotene cream as 
observed in this study. 56, 57, 58 
 
 
 
 
 According to previous studies  tazarotene was associated with a 
significantly greater incidence of patients achieving 50% or greater 
improvement compared with adapalene. But in this study adapalene was 
associated with a significantly greater incidence of patients achieving 
greater improvement. (80% vs. 50% P = 0.01). compared with 
tazarotene.56,  58, 59, 60 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 In this study, Acne Vulgaris showed increased prevalence among 
males. 
 
 The increased prevalence was noted in the age group of 15-20 
years irrespective of the sex. 
 
 In this study, pronounced incidence of acne vulgaris was noted 
among students. 
 
 The precipitating factors noted in this study were more among 
male patients. 
 
 Patients treated with 0.1% adapalene cream showed better 
response compared to patients treated with 0.1% tazarotone cream.  
 
 Among those improved with topical adapalene cream and topical 
tazarotene cream good response was observed in the age group of 
15-20 years.  
 
 Nearly 75% of the lesions resolved after 10 weeks of treatment 
with topical adapalene, where as only 30% of the lesions resolved 
with topical tazarotene.  
 
 The side effects of topical adapalene cream were very minimal and 
transient the side effects with topical tazarotene were severe and 
prolonged. 
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PROFORMA 
 
 
Name :    Date: 
 
Age   :               S.No. 
Sex   :     O.P. No. 
Occupation  
Address 
Marital Status 
Present Complaints 
Duration  
H/o Previous topical or Systemic treatment for acne 
H/o Drug Intake 
H/o precipitating factors such as  
 Sun Exposure 
 Premenstrual Flare  
 Stress 
 Smoking 
 
Past History 
H/o topical / systemic treatment for acne 
H/o any other drugs intake 
Family History 
Personal History 
Menstrual History 
General Examinations 
Systemic Examinations 
Dermatological Examination 
Distribution 
Grading 
Associated Dermatoses 
 
Follow Up 
Weeks 
Lesions 0 2 4 6 8 10 12 
Comedones        
Papules        
Pustules        
Total 
Lesions 
       
 
 
 
Side Effects 
  
 1 2 4 6 8 10 12 
Burning        
Erythema        
Peeling        
Exacerbation        
Itching        
Infection         
Other        
 
 
Response 
 
Nil Mild Moderate Good 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER  CHART 
S.NO. AGE SEX OCC DUR PPF PT TR
RESPONSE - 
WKS % RED. S.E OD 
        0 8 12    
1 15 M S 6 m sum, st T A 8 5 Nil 100 E  
2 15 F S 1 y st  A 12 4 3 75 I  
3 17 M S 1 y st  A 15 4 2 86 EX  
4 16 M S 2 y sum, st  A 8 2 0 100 EX  
5 16 M S 1 y st  A 13 4 3 76  PV 
6 16 M S 1 y st T A 14 10 5 64 B  
7 17 F S 1 y sum   A 12 2 1 91  PLE 
8 17 F S 2 y st  A 14 10 4 71 E SD 
9 17 F S 1 y sum, st T A 12 8 5 58   
10 17 M S 2 y st  A 12 4 3 66 D SD 
11 18 M S 2 y  T T 9 6 5 44 B  
12 20 M S 3 y   T 12 9 6 50 E SD 
13 19 M S 1 y  smo, st  T 9 6 5 44 B SD 
14 20 M S 2 y  T T 8 5 4 50 E, D  
15 20 M S 3 y smo, st  T 8 5 4 50 D, I SD 
16 22 M S 3 y  smo  T 9 7 4 55 E, I  
17 18 M S 2 y   T 6 3 2 66   
18 19 F S 2 y sum T T 8 5 4 50 B, D PLE 
19 19 F S  2 y sum  T 8 4 4 50  SD 
20 18 M S 1 y    T 8 4 2 75   
21 17 M S 1 y st T A 9 6 3 77   
22 16 M S 2 y   A 5 3 1 80   
23 19 M S 11m   A 9 6 3 66   
24 20 M S 2 y   A 10 5 2 80 B, D  
25 19 M S 3 y   A 7 4 1 85   
26 20 M S 2 y smo  A 8 5 2 75 B  
27 19 M S 3 y   A 8 3 3 62 I  
28 19 M S 2 y   A 9 5 3 77 B PV 
29 18 M S 2 y   A 5 3 1 80   
30 17 M S 1 y st  A 9 6 3 66 B PLE 
31 16 M S 1 y   A 10 5 2 80   
32 17 M S 2 y st  A 7 4 1 85 B  
33 18 M S 2 y sum, smo T A 8 5 2 75 I  
34 20 M S 1 y smo  A 8 3 3 62 B  
35 19 M S 2 y sum, smo T A 9 5 2 77 E  
36 18 M S 1 y smo  T 8 3 2 75 P, D SD 
37 18 M S 3 y sum T T 10 5 1 90 P, D  
38 17 M S 2 y smo  T 10 6 3 70 E, B  
39 16 M S 2 y st T T 6 4 0 100   
40 17 M S 2 y sum  T 9 4 2 77 E, B  
41 17 M S 3 y st  T 8 4 0 100 I  
42 18 M S 2 y sum T T 10 5 3 70 E, B SD 
43 17 M S 1 y smo  T 7 5 4 42 I  
44 17 F S 2 y st  T 8 5 4 50 E, B  
45 18 F S 2 y st  T 7 5 4 42 I  
46 19 M S 2 y   T 10 6 5 50 E, B  
47 17 M S 1 y  smo, st T T 8 5 4 50 P  
48 17 M S 1 y st  T 10 6 4 60 E, B  
49 18 M S 2 y st  T 8 4 3 62 P PLE 
50 19 M S 2 y st T T 7 6 2 7 E, B  
51 19 M S 2 y smo  T 14 11 9 35 P  
52 21 F O 2 y  T T 13 10 8 61 I PV 
53 22 M O 2 y smo  T 11 8 5 54 E, B  
54 20 M S 2 y sum, smo T T 10 8 5 50 D  
55 24 M UE 2 y st  T 14 11 7 50 E, B PLE 
56 25 F UE 3 y st S T 12 8 6 50 D  
57 20 F O 2 y st T T 15 11 8 46 D  
58 19 M S 2 y st  T 14 8 6 57 D PLE 
59 21 M S 2 y sum, smo  T 11 5 4 63 D  
60 22 M O 3 y  T T 12 8 6 50 D  
61 22 M O 4 y sum, smo  T 9 5 4 55 D  
62 24 M UE 5 y smo T T 18 12 9 50 D  
63 25 M O 5 y smo  T 16 11 9 43 D  
64 24 M O 5 y smo T T 10 7 5 50 D  
65 23 M O 4 y smo  T 14 8 5 64 D  
66 23 M O 5 y  T T 11 7 4 63   
67 19 F S 4 y st  T 15 10 9 40  PV 
68 18 F S 3 y st T T 10 6 5 70  PV 
69 19 F S 4 y st T T 10 6 4 60  SE 
70 20 F S 4 y pm, sum  T 14 10 7 50  D 
71 19 F S 3 y st  T 12 8 6 50  D 
72 20 F S 2 y pm, sum T T 16 11 7 56  D 
73 19 F S 1 y st S T 14 9 5 64  I 
74 19 F UE 1 y pm  T 13 10 6 53  D 
75 19 M UE 1 y sum, smo T T 12 9 6 50  D 
76 24 M S 2 y smo  A 14 9 3 78   
77 26 M S 6 y sum  A 10 6 0 100   
78 26 F O 8 y pm T A 14 7 2 85  E 
79 21 F O 3 y pm  A 13 7 3 76   
80 22 F S 3 y pm S A 10 4 3 70  E, B 
81 22 F HW 4 y st  A 10 6 4 60   
82 22 F S 5 y pm S A 8 3 3 62  E 
83 23 F S 5 y st  A 10 8 4 60  I 
84 20 F S 4 y pm S A 9 4 1 88  E, B 
85 21 F O 4 y sum  A 10 6 2 60   
86 22 F HW 5 y pm S A 10 4 4 50  E 
87 23 F S 5 y sum  A 9 5 1 85  D 
88 24 F O 5 y st T A 10 7 4 60   
89 20 F S 4 y pm  A 10 7 4 60  E, B 
90 25 F O 3 y pm S A 8 5 0 100   
91 23 F O 4 y  T A 9 3 2 77  E 
92 22 F S 5 y   A 8 5 1 87  EX 
93 26 F O 8 y  T A 8 4 1 87  EX 
94 26 M UE 7 y  smo  A 7 5 0 100   
95 20 M UE 2 y smo T A 7 3 1 85  I 
96 29 M O 1 y smo  A 11 4 1 90  EX 
97 26 M UE 2 y sum, smo S A 8 5 0 100  I 
98 23 M S 2 y smo  A 7 5 1 85   
99 24 M  5 y  sum, smo S A 7 3 0 100  EX 
100 23 M  3 y sum, smo S A 9 3 2 77  I 
              
              
              
              
              
A : ADAPALENE          
B : BURNING           
D : DRYNESS           
DUR : DURATION           
E : ERYTHEMA           
Ex : EXACERBATION          
HW : HOUSE WIFE          
I : ITCHING           
M : MONTH           
OD : OTHER  DISEASES          
P : PREMENSTRUAL FLARE         
PPF : PRECIPITATING FACTOR         
PT : PREVIOUS  TREATMENT         
PLE : POLYMORPHIC LIGHT ERUPTION        
S : STUDENT           
Sum : SUMMER  EXACERBATION         
Smo : SMOKING           
ST : STRESS           
SD : SEBORRHOEIC  DERMATITIS         
RED : REDUCTION           
TR : TREATMENT          
UE : UNEMPLOYED          
O : OTHERS OCCUPATION         
OD : OTHER DISEASES          
Y : YEAR           
              
              
              
              
              
              
              
              
              
              
              
 
 
 
 
 
 
 
 
 
